

**ATRIAL ELECTROPHYSIOLOGICAL &
STRUCTURAL CHANGES IN OBESITY &
DIABETES MELLITUS**

Melissa Neo

BSc. (Hons)

Centre for Heart Rhythm Disorders

The School of Medicine

The University of Adelaide

A thesis submitted to the University of Adelaide in
fulfilment of the requirements for the degree of

DOCTOR OF PHILOSOPHY

SEPTEMBER 2016

To my beloved parents, Peter & Stella,

My sister Valerie,

& my partner Wei Wen

TABLE OF CONTENTS

ABSTRACT	VI
THESIS DECLARATION	VIII
ACKNOWLEDGEMENTS.....	IX
PUBLICATIONS AND COMMUNICATION TO LEARNED SOCIETIES	X
PRIZES AND AWARDS DURING CANDIDATURE	XII
ABBREVIATIONS.....	XIII
CHAPTER ONE	1
AN OVERVIEW OF ATRIAL FIBRILLATION.....	1
1.1 INTRODUCTION.....	1
1.1.1 <i>General introduction</i>	<i>1</i>
1.1.2 <i>Epidemiological studies.....</i>	<i>2</i>
1.1.3 <i>Treatment of AF</i>	<i>3</i>
1.2 RISK FACTORS OF ATRIAL FIBRILLATION	6
1.2.1 <i>Advancing age.....</i>	<i>7</i>
1.2.2 <i>Hypertension</i>	<i>10</i>
1.2.3 <i>Diabetes mellitus.....</i>	<i>11</i>
1.3 NOVEL RISK FACTORS OF ATRIAL FIBRILLATION	13
1.3.1 <i>Obesity.....</i>	<i>14</i>
1.3.2 <i>Obstructive sleep apnea</i>	<i>16</i>
1.3.3 <i>Summary</i>	<i>19</i>
1.4 MECHANISMS OF AF.....	24
1.4.1 <i>History.....</i>	<i>24</i>
1.4.2 <i>Early insights: rapid atrial ectopic focal activity and single circuit re-entry.....</i>	<i>25</i>
1.4.2.1 <i>The multiple wavelet hypothesis</i>	<i>27</i>
1.4.3 <i>Recent insights: rotors and wavelet breakthrough</i>	<i>28</i>
1.4.4 <i>Atrial remodeling in atrial fibrillation.....</i>	<i>33</i>
1.4.4.1 <i>Electrophysiological remodeling in AF</i>	<i>33</i>
1.4.4.2 <i>Ion channel remodeling in tachycardia-induced AF remodeling.....</i>	<i>35</i>
1.4.4.3 <i>The role of the atrial action potential (AP) in AF.....</i>	<i>36</i>
1.4.4.3.1 <i>The dynamic relationship between the effective refractory period (ERP) and the atrial AP in AF</i>	<i>40</i>
1.4.4.3.2 <i>Repolarisation alternans increases vulnerability to atrial fibrillation</i>	<i>43</i>
1.4.5 <i>Structural remodeling in AF.....</i>	<i>46</i>
1.4.5.1 <i>Atrial Fibrosis</i>	<i>47</i>
1.4.5.1.3 <i>Inflammation</i>	<i>49</i>
1.4.5.1.4 <i>Atrial dilatation</i>	<i>51</i>
1.4.5.1.5 <i>The role of gap junctions and connexins in the pathology of AF</i>	<i>55</i>
1.5 TYPE 1 AND TYPE 2 MODELS OF DIABETES EMPLOYED IN THIS THESIS	58
1.6 FURTHER RESEARCH AND FUTURE DIRECTIONS AIMS	60
CHAPTER TWO.....	62
SIMULTANEOUS CONDUCTION MAPPING AND INTRACELLULAR MEMBRANE POTENTIAL RECORDING IN ISOLATED ATRIA.....	62

2.1	INTRODUCTION.....	62
2.2	METHODS	63
2.2.1	<i>Tissue preparation.....</i>	63
2.2.2	<i>Electrophysiological study.....</i>	64
2.2.3	<i>Intracellular recording.....</i>	64
2.2.4	<i>Parameters measured</i>	65
2.2.4.1	Electrophysiological study	65
2.2.4.2	Intracellular recording	65
2.2.4.3	Statistics.....	66
2.3	RESULTS	66
2.3.1	<i>Mapping and intracellular measures during pacing</i>	66
2.3.2	<i>APD and ERP.....</i>	67
2.3.3	<i>SHIMP of tachyarrhythmia episodes.....</i>	67
2.4	DISCUSSION.....	68
2.4.1	<i>Advantages and disadvantages of the technique</i>	70
FIGURES & CAPTIONS		72
CHAPTER THREE.....		77
A RODENT MODEL OF STREPTOZOTOCIN-INDUCED TYPE 1 DIABETES: A SUBSTRATE FOR ATRIAL FIBRILLATION.....		77
3.1	INTRODUCTION.....	77
3.2	METHODS	79
3.2.1	<i>Induction of T1DM with Streptozotocin (STZ)</i>	80
3.2.2	<i>Tissue preparation.....</i>	80
3.2.3	<i>Electrophysiological study with high density mapping and simultaneous intracellular action potential recording.....</i>	80
3.2.4	<i>Parameters measured</i>	81
3.2.4.1	Animal characteristics.....	81
3.2.4.2	Electrophysiological Study	82
3.2.4.3	Intracellular Recording.....	83
3.2.4.4	Histology	83
3.2.4.5	Enzyme-linked Immunosorbent Assay (ELISA)	84
3.3	RESULTS	85
3.3.1	<i>Animal characteristics</i>	85
3.3.2	<i>Electrical remodeling.....</i>	85
3.3.2.1	High density map study.....	85
3.3.2.2	Intracellular action potential study.....	86
3.3.3	<i>Structural remodeling (Histology)</i>	86
3.3.4	<i>Plasma serum levels of inflammatory biomarkers.....</i>	87
3.4	DISCUSSION.....	87
3.4.1	<i>Systemic changes</i>	88
3.4.2	<i>Atrial electrical changes.....</i>	89
3.4.3	<i>Atrial structural changes (Histology).....</i>	92
3.4.4	<i>Inflammatory biomarkers</i>	93

3.4.5	Conclusion	95
FIGURES & TABLES	96
CHAPTER FOUR	106
DIABETES AND AGE: RISK FACTORS FOR A PROARRHYTHMIC SUBSTRATE FOR ATRIAL FIBRILLATION IN A RAT MODEL OF TYPE II DIABETES MELLITUS	106
4.1	INTRODUCTION.....	106
4.2	METHODS	108
4.2.1	Tissue preparation.....	108
4.2.2	Electrophysiological study.....	109
4.2.3	Parameters measured	110
4.2.3.1	Animal characteristics	110
4.2.3.2	Electrophysiological study	110
4.2.3.3	Histology	112
4.2.3.4	Enzyme-linked immunosorbent assay (ELISA)	112
4.3	RESULTS	113
4.3.1	Animal characteristics	113
4.3.2	Atrial electrical remodeling	114
4.3.2.1	High density map study.....	114
4.3.2.2	Intracellular action potential study.....	114
4.3.3	Atrial structural remodeling (Histology).....	115
4.3.4	Plasma serum levels of leptin and inflammatory biomarkers.....	115
4.4	DISCUSSION.....	116
4.4.1	Animal characteristics	117
4.4.2	Atrial electrophysiological remodeling.....	118
4.4.3	Atrial structural remodeling	121
4.4.4	Conclusion	126
FIGURES & TABLES	127
CHAPTER FIVE	137
FINAL DISCUSSION	137
5.1	TYPE 1 AND TYPE 2 DIABETES MELLITUS AS INDIVIDUAL RISK FACTORS OF ATRIAL FIBRILLATION	137
5.2	MECHANISMS OF DIABETES MELLITUS-INDUCED ATRIAL FIBRILLATION.....	138
5.2.1	Atrial electrical remodeling.....	139
5.2.2	Atrial structural remodeling	142
5.3	CONCLUSION.....	147
5.4	LIMITATIONS.....	147
5.5	FUTURE DIRECTIONS	152
FIGURE & CAPTION	156
REFERENCES	157

ABSTRACT

Atrial fibrillation (AF) is the most commonly presented arrhythmia in the clinical setting, and its prevalence contributes significantly towards morbidity and mortality rates in the general population. Obesity and diabetes mellitus (DM, type I and type II DM) are recognised, well established independent risk factors of AF which can occur and contribute towards the development of AF both individually and in a concomitant fashion. The pathophysiological processes by which a proarrhythmic atrial substrate is produced in obesity and DM have not been fully elucidated. Further characterisation of the atrial substrate in obesity and DM induced AF is required.

Chapter one addresses the mechanistic components which may contribute towards establishing AF, and discusses the early and current insights underlying the pathogenesis of AF; This chapter describes the current literature available on the electrophysiological and structural components which may lead to the development of a vulnerable atrial substrate; these include the role of the action potential (AP), the relationship between the AP and the effective refractory period (ERP), and the contribution of inflammation and fibrosis towards AF development.

Chapter two investigates the feasibility and result of combined application of simultaneous high density conduction mapping with intracellular membrane potential recording to better understand the genesis and maintenance of arrhythmias in the isolated atria. Described are the ability to observe changes in action potential (AP) morphology at a given recording region, regional differences in AP restitution, lack of correlation between AP duration (APD) and the atrial effective refractory period (ERP), and AP alternans in amplitude, and, duration.

Chapter three assesses electrophysiological and structural changes in a rat model of type I DM (T1DM) using streptozotocin (STZ), which preferentially exerts toxicity to the insulin-producing beta cells of the pancreas to elicit the T1DM phenotype. This chapter demonstrates the impact of untreated T1DM on the atrial myocardium. At the structural level, T1DM animals demonstrated atrial cardiomyocyte hypertrophy with increased fibrosis. At the electrophysiological level, there was an abbreviation of the ERP with increased heterogeneity in conduction, as well as prolongation of the AP.

Chapter four describes the impact of obesity, type II DM (T2DM) and age on the electrical and structural properties of the atria using the Zucker (*fa/fa*) rat model. This chapter reports cardiomyocyte hypertrophy, increased fibrosis, prolongation of the APD, increased heterogeneity and slowed conduction, with differences in ERP between the left and right atrium of the DM animals. These results highlight the potential difference between the pathogenesis of T2DM from T1DM on the atrial myocardium in the predisposition towards development of AF.

Chapter five summarises the observations made in the T1DM and T2DM studies of chapters three and four respectively; this chapter discusses the similarities and differences shared in the data obtained from the studies, with a brief description of the potential mechanisms involved in DM-induced pathogenesis of AF. Additionally, the potential importance of segregating the diabetic states as having individual and differential influences on the atrial myocardium is highlighted. Future directions and areas of further research conclude this chapter.

THESIS DECLARATION

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in my name, in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my name, for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library Search and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Melissa Neo

September 2016

ACKNOWLEDGEMENTS

I would like to thank my primary supervisor, Professor David Saint for his guidance, patience, support and mentorship over the years. I am grateful for the times he shared his wealth of knowledge, ideas, anecdotes and analogies to explain and to demonstrate the vast field of electrophysiology. I am thankful for his understanding and his kindness during my studies. I would like to thank my secondary supervisor, Professor Prashanthan Sanders for his knowledge and vigor to strive in clinical research in pursuit of unanswered questions underlying potential pathological mechanisms of atrial fibrillation. Professor Saint and Professor Sanders were integral in the conception of the studies, the design of each protocol, oversaw the analysis and interpretation of the data and review of each study. I would also like to extend thanks and appreciation to Dr. Dennis Lau for sharing his skills in high-density mapping of small animal tissue, and for his help in the analysis and interpretation of the data and in the writing process.

I am thankful for the Laboratory of Animal Services for their expertise in establishing and in the maintenance of the Zucker rat breeding colonies for which my studies were dependent on.

I am grateful and blessed to have shared this experience with my partner, Wei Wen Lim, who supported me with love and patience through the years in both the good times and the tougher moments too. I am also blessed to have the unwavering support of my family, in particular, from my parents, Peter and Stella Neo, who have continued to love and support me unconditionally. I would like to thank God for His provisions in each area of my life so that I may always be blessed, favored and loved.

PUBLICATIONS AND COMMUNICATION TO LEARNED SOCIETIES

Chapter two

1. **Manuscript:** Simultaneous conduction mapping and intracellular membrane potential recording in isolated atria. Melissa Neo, David G. Morris, Pawel Kuklik, Dennis H. Lau, Hany Dimitri, Wei-Wen Lim, Prashanthan Sanders, David A. Saint. *Canadian Journal of Physiology and Pharmacology*, 2016, 94(5): 563-569, 10.1139/cjpp-2015-0194 (Accepted manuscript)
2. **Presentation:** Presented at the Cardiac Society of Australia and New Zealand Conference, August 2011, Perth, Australia
3. **Presentation:** Presented at the Faculty of Health Sciences Postgraduate Expo, August 2011, Adelaide, Australia

Chapter three

1. **Manuscript:** A Rodent Model of Streptozotocin-Induced Type 1 Diabetes: A Substrate for Atrial Fibrillation. Melissa Neo, Wei Wen Lim, Dennis H. Lau, Prashanthan Sanders, David A. Saint. (prepared in publication format)
2. **Presentation:** Presented at the Heart Rhythm Society Conference, May 2012, Boston, United States of America
3. **Presentation:** Presented at the the Asia Pacific Heart Rhythm Society Conference, October 2012, Taipei, Taiwan
4. **Presentation:** Presented at the Australian Physiological Society Conference, November 2014, Brisbane, Australia

5. **Presentation:** Presented at the Faculty of Health Sciences Conference, September 2014, Adelaide, Australia
6. **Presentation:** Presented at the Heart Rhythm Society Conference, May 2015, Boston, United States of America
7. **Presentation:** Presented at the Cardiac Society of Australia and New Zealand (CSANZ) Conference, August 2015, Melbourne, Australia

Chapter four

1. **Manuscript:** Obesity, Diabetes and Age: Risk factors for a proarrhythmic substrate for Atrial Fibrillation in a Rat Model of Type II Diabetes Mellitus. Melissa Neo, Wei Wen Lim, Dennis H. Lau, Prashanthan Sanders, David A. Saint. (prepared in publication format)
2. **Presentation:** Presented at the Cardiac Society of Australia and New Zealand (CSANZ) Conference, August 2012, Brisbane, Queensland.
3. **Presentation:** Presented at the Asia Pacific Heart Rhythm Society (APHRS) Conference, October 2012, Taipei, Taiwan
4. **Presentation:** Presented at the the Cardiac Society of Australia and New Zealand (CSANZ) Conference, August 2013, Gold Coast, Australia
5. **Presentation:** Presented at the Cardiac Society of Australia and New Zealand (CSANZ) Conference, August 2015, Melbourne, Australia
6. **Presentation:** Presented at the Heart Rhythm Society Conference, May 2016, San Francisco, United States of America

PRIZES AND AWARDS DURING CANDIDATURE

1. International Society for Heart Research Travel Bursary for CSANZ 2013
2. Australian Physiological Society Student Travel Claim for AUPS 2014
3. International Society for Heart Research Travel Bursary for CSANZ 2015
4. Heart Foundation E O Myers Trust Fund Travel Grant 2015

ABBREVIATIONS

Abbreviation	Explanation
AF	Atrial fibrillation
ACE	Angiotensin converting enzyme
Ang II	Angiotensin II
AP	Action potential
APD ₂₀ , APD ₅₀ , APD ₈₀ , APD ₉₀	Action potential duration at 20, 50, 80, 90% of repolarisation respectively
AT1R	Angiotensin receptor type 1
BMI	Body mass index
CAF	Chronic atrial fibrillation
CamKII	Ca ²⁺ /calmodulin-dependent protein kinase II
CHF	Congestive heart failure
CHI	Conduction heterogeneity index
CPAP	Continuous positive airway pressure
CRP	C-reactive protein
CV	Conduction velocity
Cx 40, 43	Connexin 40, 43
DAD	Delayed after depolarisation
DM	Diabetes mellitus
ELISA	Enzyme-linked immunosorbent assay
EPS	Electrophysiology study
ERP	Effective refractory period
fa/fa	Zucker rat fatty gene
GLUT2	Glucose transporter 2
HbA1c	Haemoglobin A1c (Glycated haemoglobin)
hs-CRP	High-sensitivity C-reactive protein
I _{CaL}	L-type Ca ²⁺ current
ICAM-1	Intercellular Adhesion Molecule 1
IFN-γ	Interferon-γ
I _{K1}	Inward rectifier K ⁺ current

I _{Kr}	Rapid delayed rectifier K ⁺ current
I _{Ks}	Slow delayed rectifier K ⁺ current
I _{Kur}	Ultra-rapid delayed rectifier K ⁺ current
IL-1,6,8,10	Interleukin-1,6,8,10
I _{to}	K ⁺ transient outward current
IVC	Inferior vena cava
K _{ir}	Inwardly rectifying potassium channel(s)
K _v	Voltage gated potassium channel(s)
LA	Left atrium
LDL-C	Low density lipoprotein-C
LV	Left ventricle
MCP-1	Monocyte chemoattractant protein-1
MEA	Multi-electrode array
NCX	Na ⁺ /Ca ²⁺ exchanger
NDP	NanoZoomer digital pathology system
NFκB	Nuclear factor kappa-B (light-chain-enhancer of activated B cells)
OSA	Obstructive sleep apnea
P ₅ , P ₅₀ , P ₉₅	Phase mapping percentiles 5, 50 and 95
PAF	Paroxysmal atrial fibrillation
Pro-BNP	Pro B-type natriuretic peptide
RA	Right atrium
ROS	Reactive oxygen species
RV	Right ventricle
RyR	Ryanodine receptor
SAC	Stretch-activated ion channels
SERCA or SERCA2a	Sarco/endoplasmic reticulum Ca ²⁺ -ATPase
SHIMP	Simultaneous high density mapping and intracellular membrane potential recording
SR	Sarcoplasmic reticulum
STZ	Streptozotocin

SVC	Superior vena cava
T1DM	Type 1 diabetes mellitus
T2DM	Type 2 diabetes mellitus
TGF- β 1	Transforming growth factor beta 1
TIMP-1	TIMP metalloproteinase inhibitor 1
TNF- α	Tumor necrosis factor- α
Zfr	Zucker fatty rat